The T-SPOT.TB test
is an interferon-gamma release assay (IGRA) that is intended for use as an aid in the diagnosis of Mycobacterium tuberculosis infection and disease.
To our knowledge, this multicenter study that included 1819 TB patients and 1263 non-TB patients is the largest to date evaluating the performance of the T-SPOT.TB test
for diagnosing TB in high-burden settings.
To further determine whether the use of T-SPOT.TB test
on CSF could be an accurate diagnostic method for TBM, we therefore conducted a prospective, blinded study to evaluate the performance of circulating and localized mononuclear cell-based enzyme-linked immunospot (ELISPOT) assays that included 100 subjects with suspected TBM in China.
, QuantiFERON-TB Gold &QuantiFERON-TB Gold-in tube tests).
Newer tests include QuantiFERON-TB Gold In-Tube test (Cellestis Limited, Carnegie, Victoria, Australia, 2007) and the T-SPOT.TB test
(Oxford Immunotec Limited, Abingdon, United Kingdom).
The two Food and Drug Administration--approved IGRAs on the market are Cellistis's QuantiFERON-TB Gold In-Tube test and Oxford Immunotec's T-SPOT.TB test
. The test results are reported from the laboratory as positive, negative, or indeterminate.
The IGRA tests referred to are (ELISA)-based QuantiFERON-TB Gold In-Tube assay (QFT; Cellestis, Melbourne, Australia) and enzyme-linked immunospot (ELISPOT)-based T-SPOT.TB test
(Oxford Immunotec, Abingdon, U.K.).
Wrighton-Smith will reaffirm fourth quarter 2018 growth expectations previously communicated, including double-digit T-SPOT.TB test
volume growth in the U.S., strong year-over-year revenue growth in Asia, and an acceleration in year-over-year revenue growth in Europe & ROW.
result was positive for tuberculosis.